Alesta Therapeutics Secures €65M Series A to Advance Rare Disease Treatments

• Alesta Therapeutics has secured an oversubscribed €65 million Series A funding round co-led by Frazier Life Sciences and Droia Ventures.

• The funds will support the development of two oral therapies, ALE1 for hypophosphatasia (HPP) and ALE2 for specific forms of Charcot-Marie-Tooth (CMT), with clinical trials set to begin in 2025.

Alesta Therapeutics, a biotechnology company focused on small molecule therapies for rare diseases, has announced the successful closing of a €65 million Series A financing round. The oversubscribed round was co-led by Frazier Life Sciences and Droia Ventures, with additional participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital, and SSI Strategy. The funding will accelerate the development of Alesta’s lead drug candidates, ALE1 and ALE2, both of which are designed for oral administration.

ALE1 is an investigational treatment for hypophosphatasia (HPP), a rare genetic disorder caused by ALPL gene mutations that impair bone and tooth mineralization. The condition affects approximately 50,000 patients in the US and 75,000 in the EU, including the UK. ALE1 targets a novel mechanism to reduce levels of inorganic pyrophosphate (PPi), a key factor in disease progression. Preclinical studies have demonstrated its effectiveness in reducing PPi levels across multiple animal models. Currently advancing through GLP toxicology studies, ALE1 is expected to enter clinical trials in 2025. The asset was in-licensed from 1cBio, whose team continues to support Alesta.

In parallel, Alesta is developing ALE2 to treat specific forms of Charcot-Marie-Tooth (CMT), an inherited peripheral neuropathy affecting more than 10,000 patients in the US, EU, and Japan. ALE2 works by inhibiting GCN2, a regulator of the Integrated Stress Response (ISR), which becomes activated due to ribosomal stalling caused by tRNA synthase mutations. Preclinical data has identified ALE2 as a promising candidate for clinical development.

“Closing this financing marks an important moment for Alesta,” said Ilan Ganot, Chief Executive Officer of Alesta Therapeutics. “With the support of our investors, the expertise and commitment of our team, and collaborations with leading academics and disease advocacy groups, we are poised to make significant strides in addressing the unmet needs of patients with rare diseases. This funding enables us to advance ALE1 toward clinical proof of concept and accelerate the development of ALE2, bringing us closer to delivering transformative therapies to those who need them most.”